deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03597295

A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)

A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

Sponsor: Incyte Corporation

Conditions Squamous Cell Carcinoma of Anal Canal
Interventions Retifanlimab
Updated 16 times since 2018 Last updated: Aug 19, 2025 Started: Oct 8, 2018 Primary completion: Jun 8, 2020 Completion: Nov 10, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Squamous Cell Carcinoma of Anal Canal, this trial is completed. The trial is conducted by Incyte Corporation and has accumulated 16 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~May 2019 · 7 months · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Mar 2020 · 7 months · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Dec 2022 · 10 months · monthly snapshot~Dec 2022 – ~Jul 2024 · 19 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jul 2024 [monthly]

    Completed PHASE2

  5. Feb 2022 — Dec 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 11 earlier versions

  1. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  2. May 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  5. Aug 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

  6. May 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Mar 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Aug 2019 — Mar 2020 [monthly]

    Recruiting PHASE2

  9. May 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  10. Oct 2018 — May 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Aug 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Incyte Corporation
Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Ancona, Italy , Antwerp, Belgium , Barcelona, Spain , Bergen, Norway , Besançon, France , Brighton, United Kingdom , Brindisi, Italy , Brussels, Belgium , Catania, Italy and 32 more locations